11 chapters across the catalog
FDA Approval Confusion and Comirnaty vs. Pfizer-BioNTech
The hosts debate the legal distinction between the FDA-approved Comirnaty vaccine and the Pfizer-BioNTech vaccine currently distributed under Emergency Use Authorization. They suggest the lack of full approval for the widely available version provides "plausible deniability" for manufacturers regarding liability.
Comirnaty Advertisements, Pediatric Vaccines, FDA Approval
The hosts discuss the emergence of television advertisements for Comirnaty, the FDA-approved version of the Pfizer-BioNTech vaccine. They note the ads specifically target teenagers and children, and they mock the extensive list of side effects required in the commercial's fine print.
Representative Thomas Massie, an MIT-educated engineer, challenged the legality of military vaccine mandates during a congressional markup. Massie argued that the military has not administered the FDA-approved "Comirnaty" version of the vaccine, instead using the Emergency Use Authorization (EUA) version. He contends that discharging service members based on these mandates is a violation of federal law.
Military Vaccine Bait and Switch, Congressional Debate
Congressional members debated whether the Department of Defense engaged in a "bait and switch" by requiring vaccines that were not the specific FDA-approved doses. Representative Thomas Massie and others argued that the Secretary of Defense's mandate was illegal because the approved labels were not available to troops. The discussion also touched on the disproven notion that the vaccines prevent the spread of the virus.
Dr. Anthony Fauci appeared on CNN to recommend indoor masking in "orange" zones due to high infection dynamics. He also confirmed that the FDA is actively considering a second booster shot for Americans under the age of 50. Questions remain regarding why the Pfizer vaccine continues to operate under Emergency Use Authorization rather than full approval.
Comirnaty Licensing, Pfizer Risk Management, and Military Trials
The Department of Defense is accused of using service members as a giant study group for mRNA vaccines under a 158-page Risk Management Plan. The discussion focuses on the legal distinction between the FDA-approved Comirnaty and the Emergency Use Authorization (EUA) versions actually being administered. The hosts highlight the withdrawal of the BLA license on the same day it was granted.
Pfizer, Comirnaty Rebranding and Market Competition
A whistleblower report from the Pfizer supply chain reveals that the company is retiring the "purple cap" BioNTech vaccine in favor of the "gray cap" Comirnaty. This transition from Emergency Use Authorization (EUA) to a licensed product is seen as a move to clear inventory and potentially block competitors like Moderna and Janssen, who rely on EUA status. The move also paves the way for the approval of Pfizer's therapeutic pill, Paxlovid.
FDA Vaccine Labeling and Legal Distinction Debate
The hosts examine an FDA footnote stating that while the licensed Pfizer vaccine (Comirnaty) and the Emergency Use Authorization (EUA) version have the same formulation, they are "legally distinct." This leads to a discussion about the potential reasons for this distinction, ranging from liability protections to more conspiratorial theories about "self-assembling nanotechnology." They emphasize the confusing nature of the government's official documentation regarding vaccine approval.
FDA Approval of Pfizer Comirnaty and Liability Shields
The FDA's full approval of the Pfizer-BioNTech vaccine, rebranded as Comirnaty, has created confusion regarding legal liability. While Comirnaty is approved, the existing stock of Pfizer vaccines remains under Emergency Use Authorization (EUA), which maintains a liability shield for the manufacturer. Critics argue the approval process bypassed traditional advisory committee discussions to expedite mandates.
The hosts discuss the official rebranding of COVID-19 vaccines in Australia. The Pfizer-BioNTech vaccine is being marketed as "Comirnaty," while Moderna has chosen the name "Spikevax." John C. Dvorak criticizes the name Spikevax for being too literal regarding the spike protein, comparing it to a soda company renaming its product "Sugar Will Kill You."
The Pfizer-BioNTech vaccine has been officially branded as "Comirnaty" in Europe, though it is still widely referred to by the manufacturer's name in the US. This branding strategy is compared to "Xerox" or "Kleenex," where the company name becomes synonymous with the product, solidifying Pfizer's market dominance.
